Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation

Gilead Sciences, Inc. and Dragonfly Therapeutics announced a collaboration designed to advance a number of Dragonfly’s novel NK cell engager-based immunotherapies for oncology and inflammation indications.